Cargando…

Field evaluation of piglet vaccination with a Mycoplasma hyopneumoniae bacterin as compared to a ready-to-use product including porcine circovirus 2 and M. hyopneumoniae in a conventional French farrow-to-finish farm

BACKGROUND: A controlled randomized trial was performed on a well-managed conventional French 180-sow farm. The trial compared the growth performances of piglets vaccinated at weaning (single shot) either with a commercial monovalent Mycoplasma hyopneumoniae bacterin vaccine or with a commercial biv...

Descripción completa

Detalles Bibliográficos
Autores principales: Duivon, Didier, Corrégé, Isabelle, Hémonic, Anne, Rigaut, Martial, Roudaut, David, Jolie, Rika
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5772722/
https://www.ncbi.nlm.nih.gov/pubmed/29375890
http://dx.doi.org/10.1186/s40813-017-0077-y
_version_ 1783293456751263744
author Duivon, Didier
Corrégé, Isabelle
Hémonic, Anne
Rigaut, Martial
Roudaut, David
Jolie, Rika
author_facet Duivon, Didier
Corrégé, Isabelle
Hémonic, Anne
Rigaut, Martial
Roudaut, David
Jolie, Rika
author_sort Duivon, Didier
collection PubMed
description BACKGROUND: A controlled randomized trial was performed on a well-managed conventional French 180-sow farm. The trial compared the growth performances of piglets vaccinated at weaning (single shot) either with a commercial monovalent Mycoplasma hyopneumoniae bacterin vaccine or with a commercial bivalent vaccine (Porcilis® PCV M Hyo) against M. hyopneumoniae and porcine circovirus 2 (PCV2). The farm’s porcine reproductive and respiratory syndrome status was stable, and most diseases (enzootic pneumonia, atrophic rhinitis, post-weaning multisystemic wasting syndrome) were controlled by routine vaccination. RESULTS: During the post-weaning phase, the growth performances of the piglets vaccinated with the bivalent vaccine were not significantly different from those vaccinated with the monovalent vaccine. However, during the fattening phase the group vaccinated with the bivalent vaccine had a significantly improved ADG (+34 g/d, p = 0. 047), resulting in a 5-day earlier shipment to slaughter. The group also had a shorter and lower PCV2 load in serum during the fattening period, and an improved lung lesions score. In both groups, three pigs died during the peak PCV2 viraemia (16–23 weeks of age). Immunohistochemistry of the lymph nodes showed that in the group vaccinated with the bivalent vaccine, none of these pigs had PCV2-like lesions, while 2 out of the 3 from the other group did. Results suggest that the added PCV2 valence in the vaccination protocol helps countering the negative impact of subclinical PCV2 infection on growth. The calculated return on investment of the added PCV2 vaccine valence was €1.7 extra revenue per slaughtered pig (€ 39 additional revenue per sow and per year), despite the fact that the cost of the bivalent vaccine was higher than the monovalent M. hyopneumoniae vaccine. CONCLUSION: In this healthy conventional sow farm, the combined M. hyopneumoniae and PCV2 vaccination was efficacious, convenient to administer and profitable.
format Online
Article
Text
id pubmed-5772722
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-57727222018-01-26 Field evaluation of piglet vaccination with a Mycoplasma hyopneumoniae bacterin as compared to a ready-to-use product including porcine circovirus 2 and M. hyopneumoniae in a conventional French farrow-to-finish farm Duivon, Didier Corrégé, Isabelle Hémonic, Anne Rigaut, Martial Roudaut, David Jolie, Rika Porcine Health Manag Research BACKGROUND: A controlled randomized trial was performed on a well-managed conventional French 180-sow farm. The trial compared the growth performances of piglets vaccinated at weaning (single shot) either with a commercial monovalent Mycoplasma hyopneumoniae bacterin vaccine or with a commercial bivalent vaccine (Porcilis® PCV M Hyo) against M. hyopneumoniae and porcine circovirus 2 (PCV2). The farm’s porcine reproductive and respiratory syndrome status was stable, and most diseases (enzootic pneumonia, atrophic rhinitis, post-weaning multisystemic wasting syndrome) were controlled by routine vaccination. RESULTS: During the post-weaning phase, the growth performances of the piglets vaccinated with the bivalent vaccine were not significantly different from those vaccinated with the monovalent vaccine. However, during the fattening phase the group vaccinated with the bivalent vaccine had a significantly improved ADG (+34 g/d, p = 0. 047), resulting in a 5-day earlier shipment to slaughter. The group also had a shorter and lower PCV2 load in serum during the fattening period, and an improved lung lesions score. In both groups, three pigs died during the peak PCV2 viraemia (16–23 weeks of age). Immunohistochemistry of the lymph nodes showed that in the group vaccinated with the bivalent vaccine, none of these pigs had PCV2-like lesions, while 2 out of the 3 from the other group did. Results suggest that the added PCV2 valence in the vaccination protocol helps countering the negative impact of subclinical PCV2 infection on growth. The calculated return on investment of the added PCV2 vaccine valence was €1.7 extra revenue per slaughtered pig (€ 39 additional revenue per sow and per year), despite the fact that the cost of the bivalent vaccine was higher than the monovalent M. hyopneumoniae vaccine. CONCLUSION: In this healthy conventional sow farm, the combined M. hyopneumoniae and PCV2 vaccination was efficacious, convenient to administer and profitable. BioMed Central 2018-01-18 /pmc/articles/PMC5772722/ /pubmed/29375890 http://dx.doi.org/10.1186/s40813-017-0077-y Text en © The Author(s). 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Duivon, Didier
Corrégé, Isabelle
Hémonic, Anne
Rigaut, Martial
Roudaut, David
Jolie, Rika
Field evaluation of piglet vaccination with a Mycoplasma hyopneumoniae bacterin as compared to a ready-to-use product including porcine circovirus 2 and M. hyopneumoniae in a conventional French farrow-to-finish farm
title Field evaluation of piglet vaccination with a Mycoplasma hyopneumoniae bacterin as compared to a ready-to-use product including porcine circovirus 2 and M. hyopneumoniae in a conventional French farrow-to-finish farm
title_full Field evaluation of piglet vaccination with a Mycoplasma hyopneumoniae bacterin as compared to a ready-to-use product including porcine circovirus 2 and M. hyopneumoniae in a conventional French farrow-to-finish farm
title_fullStr Field evaluation of piglet vaccination with a Mycoplasma hyopneumoniae bacterin as compared to a ready-to-use product including porcine circovirus 2 and M. hyopneumoniae in a conventional French farrow-to-finish farm
title_full_unstemmed Field evaluation of piglet vaccination with a Mycoplasma hyopneumoniae bacterin as compared to a ready-to-use product including porcine circovirus 2 and M. hyopneumoniae in a conventional French farrow-to-finish farm
title_short Field evaluation of piglet vaccination with a Mycoplasma hyopneumoniae bacterin as compared to a ready-to-use product including porcine circovirus 2 and M. hyopneumoniae in a conventional French farrow-to-finish farm
title_sort field evaluation of piglet vaccination with a mycoplasma hyopneumoniae bacterin as compared to a ready-to-use product including porcine circovirus 2 and m. hyopneumoniae in a conventional french farrow-to-finish farm
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5772722/
https://www.ncbi.nlm.nih.gov/pubmed/29375890
http://dx.doi.org/10.1186/s40813-017-0077-y
work_keys_str_mv AT duivondidier fieldevaluationofpigletvaccinationwithamycoplasmahyopneumoniaebacterinascomparedtoareadytouseproductincludingporcinecircovirus2andmhyopneumoniaeinaconventionalfrenchfarrowtofinishfarm
AT corregeisabelle fieldevaluationofpigletvaccinationwithamycoplasmahyopneumoniaebacterinascomparedtoareadytouseproductincludingporcinecircovirus2andmhyopneumoniaeinaconventionalfrenchfarrowtofinishfarm
AT hemonicanne fieldevaluationofpigletvaccinationwithamycoplasmahyopneumoniaebacterinascomparedtoareadytouseproductincludingporcinecircovirus2andmhyopneumoniaeinaconventionalfrenchfarrowtofinishfarm
AT rigautmartial fieldevaluationofpigletvaccinationwithamycoplasmahyopneumoniaebacterinascomparedtoareadytouseproductincludingporcinecircovirus2andmhyopneumoniaeinaconventionalfrenchfarrowtofinishfarm
AT roudautdavid fieldevaluationofpigletvaccinationwithamycoplasmahyopneumoniaebacterinascomparedtoareadytouseproductincludingporcinecircovirus2andmhyopneumoniaeinaconventionalfrenchfarrowtofinishfarm
AT jolierika fieldevaluationofpigletvaccinationwithamycoplasmahyopneumoniaebacterinascomparedtoareadytouseproductincludingporcinecircovirus2andmhyopneumoniaeinaconventionalfrenchfarrowtofinishfarm